Peptide Protocol
Peptide Protocol
 App Store

Cagrilintide: the complete guide

Cagrilintide is a long-acting amylin analog developed for once-weekly subcutaneous dosing. It is being studied primarily in combination with semaglutide (CagriSema) for obesity and type 2 diabetes.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassLong-acting amylin analog
Half-lifeApproximately 6 days (once-weekly dosing)
Typical doseTrial titration: 0.16 → 0.30 → 0.60 → 1.2 → 2.4 mg weekly
CategoryMetabolic / amylin
Research useObesity research, type 2 diabetes, combination with GLP-1 agonists
FDA statusInvestigational. Not FDA approved. Developed for combination with semaglutide (CagriSema).

How Cagrilintide works

Cagrilintide activates amylin (CTR/RAMP) receptors, slowing gastric emptying and promoting satiety via complementary pathways to GLP-1. Combined with GLP-1 agonism, it produces additive appetite suppression.

Typical Cagrilintide dosage

Commonly reported research ranges: Trial titration: 0.16 → 0.30 → 0.60 → 1.2 → 2.4 mg weekly.

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute Cagrilintide

A widely used reconstitution for a 5 mg vial is 2 ml of bacteriostatic water. With a typical 450 mcg dose this works out to the unit count shown in the calculator below.

Open the Cagrilintide reconstitution calculator →

Pre-filled with the common 5 mg + 2 ml ratio. Adjust for your own vial.

Half-life and administration frequency

Approximately 6 days (once-weekly dosing).

This half-life informs how often Cagrilintide is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common Cagrilintide stacks

Full editorial stack guides featuring Cagrilintide:

Semaglutide + Cagrilintide

Users who plateau on semaglutide alone, pursuing tirzepatide-range weight loss without switching classes, clinical replications of the CagriSema program.

Fat lossMetabolic

Storage and handling

Lyophilized: refrigerated. Reconstituted: refrigerated, use within 28 days.

FDA and regulatory status

Investigational. Not FDA approved. Developed for combination with semaglutide (CagriSema).

Cagrilintide clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your Cagrilintide protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is Cagrilintide?

Cagrilintide is a long-acting amylin analog developed for once-weekly subcutaneous dosing. It is being studied primarily in combination with semaglutide (CagriSema) for obesity and type 2 diabetes.

How does Cagrilintide work?

Cagrilintide activates amylin (CTR/RAMP) receptors, slowing gastric emptying and promoting satiety via complementary pathways to GLP-1. Combined with GLP-1 agonism, it produces additive appetite suppression.

What is a typical Cagrilintide dose?

Commonly reported ranges are Trial titration: 0.16 → 0.30 → 0.60 → 1.2 → 2.4 mg weekly. This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of Cagrilintide?

Approximately 6 days (once-weekly dosing). This influences how often it is administered.

How do you reconstitute Cagrilintide?

A common approach is to add 2 ml of bacteriostatic water to a 5 mg vial. Use the reconstitution calculator for exact unit counts.

What are the side effects of Cagrilintide?

Nausea and vomiting during titration; Injection-site reactions; Limited long-term safety data.

Is Cagrilintide FDA approved?

Investigational. Not FDA approved. Developed for combination with semaglutide (CagriSema).

Are there clinical trials for Cagrilintide?

Registered or published clinical-trial sources for Cagrilintide are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. Cagrilintide literature (PubMed) — National Library of Medicine. Primary research on cagrilintide pharmacology and clinical effect
  2. CagriSema clinical trial records — ClinicalTrials.gov. Phase II/III studies of cagrilintide and the CagriSema combination
  3. Enebo et al. — Safety and efficacy of cagrilintide + semaglutide — PubMed. Early CagriSema combination trial data

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.